Table 1.

Patient and tumor characteristics

Baseline characteristics
		Olaparib (N = 30)	Olaparib plus bevacizumab (N = 27)	Niraparib (N = 60)
Age
	≦49	7 (23.3%)	4 (14.8%)	7 (11.7%)
	50–59	6 (20.0%)	7 (25.9%)	13 (21.7%)
	60–69	9 (30.0%)	8 (29.6%)	17 (28.3%)
	70–79	7 (23.3%)	8 (29.6%)	19 (31.7%)
	≧80	1 (3.3%)	0 (0.0%)	4 (6.7%)
BMI
	<18.5	4 (13.3%)	1 (3.7%)	7 (11.7%)
	18.5–24.9	22 (73.3%)	21 (77.8%)	40 (66.7%)
	25.0–29.9	3 (10.0%)	4 (14.8%)	10 (16.7%)
	30.0–34.9	1 (3.3%)	1 (3.7%)	3 (5.0%)
	≧35.0	0 (0.0%)	0 (0.0%)	0 (0.0%)
Stage
	III	18 (60.0%)	19 (70.4%)	29 (48.3%)
	IV	12 (40.0%)	8 (29.6%)	31 (51.7%)
Histology
	High-grade serous carcinoma	30 (100.0%)	24 (88.9%)	42 (70.0%)
	Endometrioid carcinoma	0 (0.0%)	1 (3.7%)	5 (8.3%)
	Clear cell carcinoma	0 (0.0%)	0 (0.0%)	3 (5.0%)
	Other types carcinoma	0 (0.0%)	2 (7.4%)	3 (5.0%)
	Unclassified carcinoma	0 (0.0%)	0 (0.0%)	7 (11.7%)
Primary debulking surgery
	Present	8 (26.7%)	9 (33.3%)	9 (15.0%)
	Absent	22 (73.3%)	18 (66.7%)	51 (85.0%)
Interval debulking surgery
	R0	12 (40.0%)	15 (55.5%)	24 (40.0%)
	R1	10 (33.3%)	11 (40.7%)	16 (26.7%)
	R2	6 (20.0%)	1 (3.7%)	9 (15.0%)
	Unknown	2 (6.7%)	0 (0.0%)	11 (18.3%)
Germline BRCA1/2 status
	Pathogenic variant	30 (100.0%)	7 (25.9%)	0 (0.0%)
	VUS	0 (0.0%)	0 (0.0%)	1 (1.7%)
	Wild type	0 (0.0%)	8 (29.6%)	24 (40.0%)
	Not analyzed	0 (0.0%)	12 (44.4%)	35 (58.3%)
Tumor HRD status
	HRD&tBRCA-	0 (0.0%)	17 (63.0%)	2 (3.3%)
	HRD&tBRCA+	4 (13.3%)	10 (37.0%)	0 (0.0%)
	HRP	0 (0.0%)	0 (0.0%)	14 (23.3%)
	Not analyzed	26 (86.7%)	0 (0.0%)	44 (73.3%)
Response to the last platinum therapy
	Complete response	20 (66.7%)	21 (77.8%)	37 (61.7%)
	Partial response	10 (33.3%)	6 (22.2%)	23 (38.3%)

BMI, body mass index; VUS, variant of unknown significance; HRD: homologous recombination deficient.